The German Pediatric Oncology (GPO) Cooperative Study on Ewing’s Sarcoma

Author(s):  
K. Winkler ◽  
H. Juergens
1995 ◽  
Vol 31 ◽  
pp. S250
Author(s):  
O. Oberlin ◽  
N.B. Bui ◽  
N. Dohollou ◽  
M.C. Demaille ◽  
M. Brunat-Mentigny ◽  
...  

Author(s):  
D. Yu. Yurchenko ◽  
S. A. Kuznetsov ◽  
Yu. Yu. Kozel ◽  
E. M. Frantsiyants ◽  
G. A. Mkrtchyan ◽  
...  

Relevance. One of the leading positions among malignant tumors of the musculoskeletal system in children and adolescents has recently begun to be occupied by Ewing’s sarcoma (ES). The prognosis of patients suffering from this onconosology remains extremely unfavorable even in the absence of distant metastases and timely initiation of antitumor treatment. The authors present 10 years of experience in the management of pediatric and adolescent patients with ES in the pediatric oncology department of the National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included pediatric and adolescent patients diagnosed with ES of I—IV stages of various localizations, who were treated in the Pediatric Oncology Department of the National Medical Research Center of Oncology, Ministry of Health of Russia in the period from 2009 to 2019. We analyzed 2- and 5-year overall (OS) and event-free (EFS) survival in patients who received combined and complex antitumor treatment for various forms of tumor dissemination according to the EURO-EWING 2008protocol, which included neo-and adjuvant polychemotherapy, including high-dose, radical surgical treatment, and also radiation therapy.Results. The median 5-year OS and EFS in the general group of the studied formulations was 60 and 17 months, respectively. The indicators of 2- and 5-year OS and EFS in patients of the general group were 80.6 % and 56.7 %, 38.6 % and 10.6 %, respectively. The volume of the performed antitumor treatment, as well as the form of the advanced tumor process, did not have a significant effect on OS and EFS indicators (p > 0.05). At the same time, the chances of developing ES in boys were statistically significantly higher by 2.2 times in comparison with girls (95 % confidence interval 1.1—4.3).Conclusion. The obtained OS and EFS indices indicate unsatisfactory results of anticancer therapy and extremely high aggressiveness of the biological behavior of the tumor, regardless of the form of spread of the tumor process.


1994 ◽  
Vol 25 (3) ◽  
pp. 304-307 ◽  
Author(s):  
E.J. Perlman ◽  
P.S. Dickman ◽  
F.B. Askin ◽  
H.E. Grier ◽  
J.S. Miser ◽  
...  

2012 ◽  
Vol 47 (4) ◽  
pp. 446-450 ◽  
Author(s):  
Davi Gabriel Bellan ◽  
Reynaldo Jesus-Garcia Filho ◽  
Jairo Greco Garcia ◽  
Marcelo de Toledo Petrilli ◽  
Dan Carai Maia Viola ◽  
...  

1992 ◽  
Vol 10 (9) ◽  
pp. 1407-1412 ◽  
Author(s):  
O Oberlin ◽  
J L Habrand ◽  
J M Zucker ◽  
M Brunat-Mentigny ◽  
M J Terrier-Lacombe ◽  
...  

PURPOSE To undertake a new protocol with the goals of improving the chemotherapeutic treatment of pediatric Ewing's sarcoma by introducing ifosfamide, and to widen the indications for surgical resection of Ewing's tumor to obtain better local control and to reduce radiation doses. PATIENTS AND METHODS The French Society of Pediatric Oncology initiated its first cooperative Ewing's sarcoma study in 1978, using a four-drug regimen (cyclophosphamide, dactinomycin, Adriamycin [doxorubicin; Farmitalia Carlo Erba, Rueil-Malmaison, France], and vincristine). Ninety-five patients were included, and, at 5 years, the disease-free survival reached a plateau of 51%. After encouraging responses of recurrent soft tissue or bone sarcomas to ifosfamide, a second study began in 1984 using a new chemotherapy regimen in which cyclophosphamide was replaced by ifosfamide. Sixty-five patients were treated. RESULTS By February 1992, the median follow-up was 5.8 years. The estimated 5-year disease-free survival was 52%. We observed unexpected cardiac toxicity. Three patients experienced acute cardiac failure that was lethal in two cases. The acute toxicity of ifosfamide prompted us to stop the protocol. Retrospectively, the lack of efficacy reinforced our decision. CONCLUSION We conclude that ifosfamide did not improve the outcome of the patients despite the fact that these two treatment regimens were not randomized.


Sign in / Sign up

Export Citation Format

Share Document